Admedus (AHZ, Add, Price Target A$0.20) AHZ posted a solid 3QFY15 result with revenue up 47% to A$2.4m. We estimate the key CardiolCel® sales were approximately A$800,000 with now over 60 centres in US and Europe using the device. Following the recent capital raising, AHZ is well funded and a number of key catalysts over the coming quarters will likely see the share price recover from the current levels. Add maintained. Report attached